Compare Micron Technology, Inc. (MU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Micron Technology, Inc. trades at $888.69 (market cap $972.41B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: Micron Technology, Inc. is far larger — about 546.3× Recursion Pharmaceuticals Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MU | RXRX | |
|---|---|---|
Market Cap | $972.41B | $1.78B |
Sector | Technology | Health |
52-Week High | $1.21K | $6.79 |
52-Week Low | $115.79 | $2.84 |
Enterprise Value | $952.76B | $1.30B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $877.57, down 0.44% on the day, with technical indicators showing a neutral overall signal and bullish moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $25.11 versus $20.98 expected, driven by robust AI memory demand. Revenue surged to $37.38 billion in 2025, with net income margin at 55.91%. Analyst consensus is overwhelmingly bullish with an 81.43% buy rating and a $1,540 price target.
Outlook remains positive due to structural demand for high-bandwidth memory in AI, but risks include cyclical pricing pressures and competitive capacity expansions. The stock offers growth potential amid tight supply conditions, though volatility from valuation concerns and macroeconomic factors persists. Key support sits at $848 with resistance at $906.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
